Quick Answer
10x Genomics, Inc. reported Total Revenue of $642.82 million for the year ending 2025.
- 10x Genomics, Inc. showed an increase of +5.2% in Total Revenue from 2024 to 2025.
- This data is from 10x Genomics, Inc.'s annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2017 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $27.41 million | Q2 2018: $31.74 million | Q3 2018: $36.61 million | Q4 2018: $50.55 million | Q1 2019: $53.58 million | Q2 2019: $55.82 million | Q2 2019: $55.82 million | Q3 2019: $61.21 million | Q3 2019: $61.21 million | Q4 2019: $75.29 million | Q1 2020: $71.91 million | Q1 2020: $71.91 million | Q2 2020: $42.91 million | Q3 2020: $71.82 million | Q1 2021: $105.82 million | Q2 2021: $115.84 million | Q3 2021: $125.30 million | Q1 2022: $114.50 million | Q2 2022: $114.61 million | Q3 2022: $131.07 million | Q1 2023: $134.29 million | Q2 2023: $146.82 million | Q3 2023: $153.64 million | Q1 2024: $141.01 million | Q2 2024: $153.10 million | Q3 2024: $151.65 million | Q1 2025: $154.88 million | Q2 2025: $172.91 million | Q3 2025: $149.00 million.
- Over the full 11 years of available data (2017 to 2025), 10x Genomics, Inc.'s Total Revenue has grown by 804.3%.
- Historical annual values: Fiscal year 2025: $642.82 million | Fiscal year 2024: $610.79 million | Fiscal year 2023: $618.73 million | Fiscal year 2022: $516.41 million | Fiscal year 2021: $490.49 million | Fiscal year 2020: $298.85 million | Fiscal year 2019: $245.89 million | Fiscal year 2019: $245.89 million | Fiscal year 2018: $146.31 million | Fiscal year 2018: $146.31 million | Fiscal year 2017: $71.09 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: